Developing Clinical Tests for Better Outcomes with Immunotherapy for Patients with Mesothelioma Wednesday, March 17, 2021 Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition. Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy. Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response. “The biggest barrier to new therapies in Mesothelioma is not having a meaningful way to identify specific subsets of patients that may respond better to specific immunotherapy treatments,” says Dr. Cottrell. “As a pathologist and immunologist, I study immune responses in human tumour tissues at the microscopic level.” Read the full article here.
